Controlling hypereosinophilic syndrome (HES) means bringing your eosinophil count down to normal levels and keeping it there to prevent organ damage. The condition is diagnosed when your absolute eosinophil count exceeds 1,500 per microliter on at least two separate blood tests, and treatment typically starts with corticosteroids before moving to more targeted options depending on your specific subtype.
HES isn’t a single disease. It’s a group of disorders that share one feature: persistently high eosinophils, a type of white blood cell that causes inflammation and tissue damage when it accumulates. How you control it depends on what’s driving those counts up, which organs are affected, and whether you carry a specific genetic mutation.
Why the Subtype Matters
One of the first things your care team will do is test for a genetic abnormality called the FIP1L1-PDGFRA fusion gene. This matters because patients who carry this mutation respond dramatically well to a targeted oral medication (imatinib) at doses as low as 100 mg per day. In a study of 376 patients referred to a UK reference lab for persistent unexplained eosinophilia, those who tested positive for this fusion gene achieved rapid and deep remissions on targeted therapy. If you don’t carry the mutation, your treatment path looks different.
Testing involves a specialized blood or bone marrow analysis. The results shape everything that follows, so this step isn’t optional.
Corticosteroids as First-Line Treatment
For patients without the FIP1L1-PDGFRA mutation, corticosteroids are the starting point. The standard approach is a five-day course of prednisone at roughly 60 mg per day. Corticosteroids work quickly and reliably to suppress eosinophil production, which is why they’re the go-to in nearly every case.
Once your eosinophil count normalizes and symptoms improve, the dose gets tapered slowly. The goal is to reach 10 mg of prednisone (or less) per day, ideally on an alternate-day schedule to minimize side effects. This tapering process takes patience. Dropping the dose too fast can trigger a rebound in eosinophil levels.
Some patients, particularly those with a lymphocyte-driven form of HES, need higher maintenance doses of 30 to 60 mg daily to stay in remission. That’s a significant amount of corticosteroid over time, and it comes with real consequences: bone thinning, weight gain, elevated blood sugar, mood changes, and increased infection risk. If you need that much prednisone to stay controlled, your doctor will likely look at adding a steroid-sparing therapy.
Biologic Therapy for Steroid-Resistant HES
For patients who can’t taper off steroids or whose eosinophils don’t respond adequately, biologic medications offer a more targeted option. One FDA-reviewed biologic works by blocking a signaling protein that tells your bone marrow to produce eosinophils. It’s given as a subcutaneous injection once every four weeks.
The results can be striking. In clinical trials, patients receiving the injection saw eosinophil counts drop by 82% to 91% from baseline, depending on the dose. Some patients’ counts fell to as low as 52 cells per microliter, well within the normal range. These reductions began within three days of the first dose and deepened over the following weeks.
Biologics don’t work for everyone, but for those who respond, they can replace or significantly reduce the need for daily steroids.
What “Controlled” Actually Looks Like
The target is straightforward: normalize your eosinophil count (typically below 500 per microliter) and resolve symptoms. But controlling HES isn’t just about the number on a blood test. It’s about preventing the slow, sometimes silent damage that elevated eosinophils cause to your organs.
The skin, lungs, and gastrointestinal tract are the most commonly affected, but any organ system can be involved. The most dangerous complication is cardiac. Eosinophils can infiltrate heart tissue, causing a condition called endomyocardial fibrosis, where scar tissue builds up inside the heart. This can also trigger blood clots. Cardiac involvement is the leading cause of serious illness and death in HES, which is why monitoring goes well beyond a simple blood count.
Ongoing Monitoring to Catch Problems Early
Living with HES means regular surveillance, even when you feel fine. The standard monitoring schedule includes several components:
- Heart: Troponin blood tests, an electrocardiogram (ECG), and an echocardiogram are used to check for cardiac involvement. If anything looks abnormal, a cardiac MRI provides more detailed imaging. Heart tissue damage from eosinophils can be patchy, so a single normal test doesn’t rule out problems entirely.
- Lungs: Chest imaging and pulmonary function tests catch inflammation or scarring that may not cause obvious symptoms yet.
- Abdomen: CT scans of the chest, abdomen, and pelvis screen for an enlarged spleen, swollen lymph nodes, and hidden tumors that could be driving the eosinophilia.
- Affected tissues: When feasible, biopsies of involved organs help confirm the extent of eosinophil infiltration.
Progression can happen over time even with treatment, so these tests aren’t one-and-done. They’re repeated at intervals your specialist determines based on your disease severity.
Managing Triggers That Spike Eosinophils
While HES itself is a chronic condition driven by internal dysfunction, external factors can make eosinophil counts harder to control. Allergies are the most common cause of elevated eosinophils in general, and if you have HES alongside allergic conditions like asthma, chronic sinusitis, or seasonal allergies, uncontrolled allergic inflammation can push your counts higher.
Allergy testing can identify specific triggers, whether environmental (pollen, dust mites, mold) or dietary. Treating those allergies with antihistamines, nasal corticosteroids, or allergen avoidance can reduce the “background noise” of eosinophil production, making your HES medications more effective.
Medications themselves are another overlooked trigger. Certain drugs can independently cause eosinophilia. If you start a new medication and notice your counts climbing, that connection is worth flagging with your specialist. Stopping or switching the offending drug often resolves the spike.
Life-Threatening Flares
HES can occasionally present with or escalate to immediately dangerous levels. When life-threatening complications are present or imminent, such as acute heart involvement or severe blood clots, treatment intensifies rapidly. High-dose intravenous corticosteroids are used in these situations, with dosing that can be many times higher than the standard oral regimen.
These emergencies are why keeping eosinophil counts consistently controlled matters so much. The goal of long-term management is to prevent you from ever reaching that point. Regular blood work, consistent medication adherence, and ongoing communication with your hematologist or allergist-immunologist form the foundation of staying ahead of the disease rather than reacting to crises.